The news from Down Under is grim. Australia has recorded its first diphtheria death in what is now the worst outbreak of the disease in decades. As UK health experts monitor the situation with understandable concern, the market-minded observer sees a troubling pattern: a failure of public health investment that mirrors the fiscal incontinence we have warned about for years.
Consider the numbers. Diphtheria, a disease easily prevented by vaccination, has made a comeback in Australia largely due to gaps in immunisation coverage. These gaps are not accidents; they are the predictable consequence of underfunded public health programmes and a creeping complacency among the populace. When governments cut corners on preventive care, the bill always comes due, and it is always higher than the original saving.
Here in Britain, the parallels are alarming. Our NHS is a sacred cow, but its budget has been stretched thin by years of political meddling and an ageing population. The result? Falling vaccination rates for childhood diseases, including diphtheria. The UK Health Security Agency is right to monitor the Australian outbreak, but monitoring is not action. We need to ask: are we spending enough on vaccination campaigns? Are we tracking herd immunity closely enough? Or are we, like the Australians, kicking the can down the road?
Let me be clear: this is not a call for greater government spending on every whim. It is a call for targeted, efficient investment in the public goods only the state can provide. Vaccination is a textbook example of a public good with massive positive externalities. A pound spent on immunisation saves dozens of pounds in treatment costs and economic disruption. Yet we persist in treating public health as a cost centre rather than an investment portfolio.
The market reaction to the Australian news has been muted, but that could change. Biotech stocks with vaccine pipelines saw a slight uptick, while travel and tourism sectors did not flinch. But the real volatility will come if the outbreak spreads to the UK. An epidemic would hammer consumer confidence, disrupt supply chains, and force the government into emergency spending that would blow a hole in the fiscal accounts. The gilt market would take note, and yields would rise.
Of course, the optimists will say that the UK has higher vaccination rates than Australia, and that our health system is better prepared. But complacency is the enemy of prudence. The diphtheria bacterium is not an abstract risk; it is a live threat that exploits the gaps we leave in our defensive armour. Every child not vaccinated is a bond default waiting to happen.
What should be done? First, a comprehensive audit of childhood vaccination coverage in every local authority, with particular attention to deprived areas where uptake tends to be lower. Second, a targeted public information campaign to counter the anti-vaxxer nonsense that has confused too many parents. Third, a contingency plan for surge capacity in hospitals if the disease gains a foothold.
The cost of these measures would be trivial compared to the cost of an outbreak. This is the basic arithmetic of risk management. Yet governments, addicted to short-term thinking, often neglect it. The Australian death is a reminder that penny-wise and pound-foolish is not just a metaphor. It is a tragedy.
So as UK health experts monitor the situation, I hope they are also sharpening their pencils. The bottom line is that a life is lost, and a warning is issued. The question is whether we will heed it before the numbers turn red.
